Novo Nordisk AS (OCSE:NOVO B) Total Liabilities : kr322,309 Mil (As of Dec. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Novo Nordisk AS Total Liabilities?

Novo Nordisk AS's Total Liabilities for the quarter that ended in Dec. 2024 was kr322,309 Mil.

Novo Nordisk AS's quarterly Total Liabilities increased from Jun. 2024 (kr256,861.00 Mil) to Sep. 2024 (kr276,919.00 Mil) and increased from Sep. 2024 (kr276,919.00 Mil) to Dec. 2024 (kr322,309.00 Mil).

Novo Nordisk AS's annual Total Liabilities increased from Dec. 2022 (kr157,771.00 Mil) to Dec. 2023 (kr207,925.00 Mil) and increased from Dec. 2023 (kr207,925.00 Mil) to Dec. 2024 (kr322,309.00 Mil).

Novo Nordisk AS Total Liabilities Historical Data

The historical data trend for Novo Nordisk AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Total Liabilities Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

81,597.00

123,762.00

157,771.00

207,925.00

322,309.00

Novo Nordisk AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															207,925.00	200,010.00	256,861.00	276,919.00	322,309.00

Novo Nordisk AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Novo Nordisk AS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	217528	+	(89674	+	8778
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	5426	+	903	+	0)
	=	322,309

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	465795	-	143486
	=	322,309

Novo Nordisk AS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	217528	+	(89674	+	8778
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	5426	+	903	+	0)
	=	322,309

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	465795	-	143486
	=	322,309

Novo Nordisk AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OCSE:NOVO B) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines